|LETTER TO THE EDITOR
|Year : 2018 | Volume
| Issue : 1 | Page : 59
Adverse events during plateletpheresis donation
Department of Biological Science, Joseph Ayo Babalola University, Ilara-Mokin, Nigeria
|Date of Web Publication||21-Aug-2018|
Joseph Ayo Babalola University, Ilara-Mokin
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Wiwanitkit V. Adverse events during plateletpheresis donation. J Pharm Negative Results 2018;9:59
I read the publication on “Underreporting of mild adverse events (AEs) during plateletpheresis donations” with a great interest. Kansay noted that “it is recommended to discuss and create a system of hemovigilance for AE in donations with special consideration to mild AE which are usually underreported.” In clinical practice, the AE might be unexpected but it should not think that it is not preventable. In the present report by Kansay, the incidence was reported. However, it is not clear on how the incidence could be derived. How the AE can be observed and recorded. In details, it is also questionable how to judge an AE is mild or severe. In fact, the monitoring of AE is the basic necessary process in either pharmacological or nonpharmacological management of the patients. The reporting of the event is useful for recording. However, it should not forget a more important necessary process, the planning for preventive and corrective actions. For any centers that severe donations, there must be the quality management system that should described work instructions for the practitioners ranging from pre-, during-and post-donation phase. For any clinical settings, there must be standard procedure for observation and monitoring of AE. There should be standard recording process and/or form. Also, there should be the specific protocol for management of any possible observed AE. For the report by Kansay, the data on these interesting points is lack.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kansay S. Underreporting of mild adverse events during plateletpheresis donations. J Pharm Negat Results 2017;8:56-7.
Burgstaler EA. Blood component collection by apheresis. J Clin Apher 2006;21:142-51.